VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decrease in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totaling 70,900 shares, a drop of 68.0% from the September 15th total of 221,800 shares. Based on an average daily trading volume, of 315,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.8% of the shares of the stock are short sold. Currently, 2.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 315,800 shares, the days-to-cover ratio is currently 0.2 days.

VivoSim Labs Price Performance

NASDAQ:VIVS opened at $2.56 on Friday. VivoSim Labs has a 1-year low of $1.41 and a 1-year high of $21.96. The firm has a market cap of $6.66 million, a price-to-earnings ratio of -0.25 and a beta of 1.13. The company has a fifty day moving average of $2.81.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($1.14) earnings per share for the quarter. VivoSim Labs had a negative net margin of 1,396.48% and a negative return on equity of 32.95%. The company had revenue of $0.04 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About VivoSim Labs

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.